Aequus Pharmaceuticals Inc.
AQS.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -30.11% | -70.39% | -82.03% | -82.16% | -70.27% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -30.11% | -70.39% | -82.03% | -82.16% | -70.27% |
| Cost of Revenue | 24.91% | -23.08% | -32.86% | 5.51% | 101.07% |
| Gross Profit | -49.52% | -80.78% | -88.23% | -89.15% | -77.12% |
| SG&A Expenses | -4.35% | -6.78% | -19.99% | -30.58% | -32.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.31% | -9.38% | -20.43% | -25.48% | -30.18% |
| Operating Income | 4.59% | -14.80% | -9.26% | -4.55% | -0.51% |
| Income Before Tax | 18.81% | 4.16% | 6.66% | 10.83% | -22.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.81% | 4.16% | 6.66% | 10.83% | -22.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.81% | 4.16% | 6.66% | 10.83% | -22.86% |
| EBIT | 4.59% | -14.80% | -9.26% | -4.55% | -0.51% |
| EBITDA | 4.54% | -14.91% | -9.34% | -4.61% | -0.55% |
| EPS Basic | 18.13% | 3.61% | 6.94% | 11.76% | -22.15% |
| Normalized Basic EPS | 18.42% | 3.85% | 6.48% | 10.34% | -22.58% |
| EPS Diluted | 18.13% | 3.61% | 6.94% | 11.76% | -22.15% |
| Normalized Diluted EPS | 18.42% | 3.85% | 6.48% | 10.34% | -22.58% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | -0.18% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | -0.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
